Search Within

Payal Deepak Shah

Formats
  1. Meeting Abstract (9)
  2. Book Section (4)
  3. Journal Article (3)
Groups
  1. Department of Medicine (15)
  2. Solid Tumor Oncology Division (15)
  3. Breast Medicine Service (14)
  4. GSK Faculty (12)
  5. Survivorship Research (12)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (10)

More Groups

People
  1. Maura Dickler (11)
  2. Sarat Chandarlapaty (10)
  3. Clifford Hudis (9)
  4. Mary Ellen Moynahan (8)
  5. Shanu Modi (8)
  6. Jose Baselga (7)

More People

Years
  1. 2020 (1)
  2. 2016 (1)
  3. 2015 (5)
  4. 2014 (8)
  5. 2013 (1)
Publications
  1. Journal of Clinical Oncology (6)
  2. Cancer Research (3)
  3. Pocket Oncology (3)
  4. Clinical Advances in Hematology & Oncology (1)
  5. Nature Cancer (1)
  6. PI3K-mTOR in Cancer and Cancer Therapy (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (6)
  2. American Association for Cancer Research (3)
  3. Wolters Kluwer Health | Lippincott Williams & Wilkins (3)
  4. Future Medicine (1)
  5. Humana Press Inc (1)
  6. Millennium Medical Publishing, Inc (1)

More Publishers

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • Resistance to PI3K pathway inhibition
    Book Section

    Shah, P. D.; Chandarlapaty, S.
    In Dey, N.; De, P.; Leyland-Jones, B. (Eds.) PI3K-mTOR in Cancer and Cancer Therapy (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Oncotype DX in BRCA-associated vs. sporadic breast cancers: Differences based on germline mutation status and potential implications for adjuvant systemic therapy (AST)
    Meeting Abstract

    Shah, P. D.; Patil, S.; Dickler, M. N.; Offit, K.; Hudis, C. A.; Robson, M. E.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Dickler, M. N.; Ulaner, G.; Zamora, S. J.; Sterlin, V.; Iasonos, A.; Coughlin, C. M.; Morozov, A.; Ero, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Ulaner, G.; Zamora, S.; Sterlin, V.; Iasonos, A.; Dickler, M. N.; Moynahan, M. E.; Hudis, C. A.; Baselga, J.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Clinical and histologic characterization of dermatologic adverse events front the pan-PI3K inhibitor buparlisib (BKM-120)
    Meeting Abstract

    Schindler, K.; Abraham, R.; Shah, P. D.; Chandarlapaty, S.; Paik, P. K.; Bell-Mcguinn, K.; Bajorin, D. F.; Mellinghoff, I. K.; Younes, A.; Gounder, M. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K alpha-inhibitor plus letrozole (L) or exemestane (E)
    Meeting Abstract

    Moynahan, M. E.; Sung, P.; Asham, M.; Zamora, S.; Shah, P. D.; Modi, S.; Lake, D.; D'Andrea, G.; Goldfarb, S. B.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save